Accéder au contenu
Merck

Acid sphingomyelinase regulates platelet cell membrane scrambling, secretion, and thrombus formation.

Arteriosclerosis, thrombosis, and vascular biology (2013-11-16)
Patrick Münzer, Oliver Borst, Britta Walker, Evi Schmid, Marion A H Feijge, Judith M E M Cosemans, Madhumita Chatterjee, Eva-Maria Schmidt, Sebastian Schmidt, Syeda T Towhid, Christina Leibrock, Margitta Elvers, Martin Schaller, Peter Seizer, Klaus Ferlinz, Andreas E May, Erich Gulbins, Johan W M Heemskerk, Meinrad Gawaz, Florian Lang
RÉSUMÉ

Platelet activation is essential for primary hemostasis and acute thrombotic vascular occlusions. On activation, platelets release their prothrombotic granules and expose phosphatidylserine, thus fostering thrombin generation and thrombus formation. In other cell types, both degranulation and phosphatidylserine exposure are modified by sphingomyelinase-dependent formation of ceramide. The present study thus explored whether acid sphingomyelinase participates in the regulation of platelet secretion, phosphatidylserine exposure, and thrombus formation. Collagen-related peptide-induced or thrombin-induced ATP release and P-selectin exposure were significantly blunted in platelets from Asm-deficient mice (Smpd1(-/-)) when compared with platelets from wild-type mice (Smpd1(+/+)). Moreover, phosphatidylserine exposure and thrombin generation were significantly less pronounced in Smpd1(-/-) platelets than in Smpd1(+/+) platelets. In contrast, platelet integrin αIIbβ3 activation and aggregation, as well as activation-dependent Ca(2+) flux, were not significantly different between Smpd1(-/-) and Smpd1(+/+) platelets. In vitro thrombus formation at shear rates of 1700 s(-1) and in vivo thrombus formation after FeCl3 injury were significantly blunted in Smpd1(-/-) mice while bleeding time was unaffected. Asm-deficient platelets showed significantly reduced activation-dependent ceramide formation, whereas exogenous ceramide rescued diminished platelet secretion and thrombus formation caused by Asm deficiency. Treatment of Smpd1(+/+) platelets with bacterial sphingomyelinase (0.01 U/mL) increased, whereas treatment with functional acid sphingomyelinase-inhibitors, amitriptyline or fluoxetine (5 μmol/L), blunted activation-dependent platelet degranulation, phosphatidylserine exposure, and thrombus formation. Impaired degranulation and thrombus formation of Smpd1(-/-) platelets were again overcome by exogenous bacterial sphingomyelinase. Acid sphingomyelinase is a completely novel element in the regulation of platelet plasma membrane properties, secretion, and thrombus formation.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Chlorure de fer(III) hexahydrate, ACS reagent, 97%
Sigma-Aldrich
Chlorure de fer(III) hexahydrate, reagent grade, ≥98%, chunks
Sigma-Aldrich
Chlorure de fer(III) hexahydrate, puriss. p.a., reag. Ph. Eur., ≥99%
Sigma-Aldrich
Chlorure de fer(III) hexahydrate, puriss. p.a., ACS reagent, crystallized, 98.0-102% (RT)
Sigma-Aldrich
Iron(III) chloride, sublimed grade, ≥99.9% trace metals basis
Sigma-Aldrich
Iron(III) chloride, anhydrous, powder, ≥99.99% trace metals basis
Sigma-Aldrich
Iron(III) chloride solution, purum, 45% FeCl3 basis
Sigma-Aldrich
Sphingomyelinase from Bacillus cereus, buffered aqueous glycerol solution, ≥100 units/mg protein (Lowry)
Sigma-Aldrich
Sphingomyelinase from Bacillus cereus, lyophilized powder, ≥100 units/mg protein
Sigma-Aldrich
Iron(III) chloride solution, 0.2 M in 2-methyltetrahydrofuran
Sigma-Aldrich
Sphingomyelinase from Staphylococcus aureus, buffered aqueous glycerol solution, 100-300 units/mg protein (Lowry)
Millipore
TDA Reagent, suitable for microbiology